

PC25581A
Response to Office Action For Appln. No 10/816,242

Certificate of Transmission (37 C.F.R. § 1.8);
I hereby certify that this correspondence is being
electronically transmitted via **EFS-Web** to the United
States Patent and Trademark Office, **Petitions** on this
17th day of **March** 2008.

s/ /Donna Di Maccio/
Donna Di Maccio

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
James Freddo et al.

Group Art Unit: **1614**

Serial No.: **10/816,242**

Examiner: **Shirley V. Gembeh**

Confirmation No.: **9207**

Filed: **April 1, 2004**

For: **DOSAGE FORMS AND METHODS OF
TREATMENT USING VEGFR INHIBITORS**

Sir:

PETITION FOR EXTENSION OF TIME PURSUANT TO 37 C.F.R. § 1.136(a)

Pursuant to the provisions of 37 C.F.R. § 1.136(a), it is requested that the term for response to the Office Action mailed October 18, 2007 in this patent application be extended by two months, so that the expiration for the Office Action response is extended to March 18, 2008.

Authorization is hereby provided to charge the extension fee as provided under 37 C.F.R. § 1.17, as well as any additional fees required, or to credit any overpayment, to Deposit Account 16-1445.

Respectfully submitted,

Date: March 17, 2008

/Elsa Djuardi Lemoine/
Elsa Djuardi Lemoine
Attorney for Applicants
Reg. No. 45,963

Pfizer, Inc.
Patent Dept.
10555 Science Center Drive
San Diego, CA 92121
(858) 638-6117
(858) 678-8233 (fax)